INDIA— Cambrian Bioworks, a Bangalore-based biotechnology firm, has raised US$1.45 million in seed funding to advance its innovative solutions in the rapidly growing next-generation sequencing (NGS) and molecular diagnostics markets.
The Irani family office led this funding round, which is known for investing in several private ventures worldwide.
The round also included Vaibhav Hegde, the company’s CEO and co-founder, who has been instrumental in advancing its mission.
Capital infusion is critical for Cambrian Bioworks, which is seeking to accelerate the development of its automated molecular diagnostics platforms.
The company is dedicated to enhancing the precision of medical diagnostics, particularly in the field of cancer care.
According to Vaibhav Hegde, molecular diagnostics play a crucial role in enabling precise diagnosis, disease subtyping, and therapy selection, all of which are vital for improving patient outcomes.
He emphasized that this funding marks a significant milestone in Cambrian Bioworks’ journey toward revolutionizing healthcare delivery in India and beyond.
Hari Prasad of Kyra Ventures, representing the lead investor, expressed his enthusiasm about supporting Cambrian Bioworks in its mission.
He noted that the company is developing products that address fundamental challenges in healthcare delivery, particularly in underserved niches.
Prasad highlighted the team’s commitment to elevating medical diagnostics in India, which aligns with their vision of improving healthcare access and outcomes on a global scale.
The recent funding will accelerate Cambrian Bioworks’ research and development efforts, facilitate the expansion of its team, and support its entry into international markets.
The company is expected to make significant strides in molecular diagnostics, particularly with its recent launch of the Manta nucleic acid extraction platform.
This purpose-built automation platform provides high-quality DNA and RNA for genomics and PCR testing in hospitals and laboratories, ensuring accurate and reliable results.
Building on Manta’s success, Cambrian Bioworks aims to expand the availability of automated devices for liquid biopsy testing and targeted sequencing.
These technologies are expected to profoundly impact the early detection and treatment of various diseases, particularly cancer.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE
